| View |
DR-XY25188_PI_01.pdf
|
DR-XY25188
|
Amisulpride
|
Solian
|
200 mg
|
Film-Coated Tablet
|
-
|
Delpharm Dijon
|
France
|
-
|
15 April 2021
|
03 July 2026
|
| View |
|
DR-XY25192
|
Pemirolast Potassium
|
Alegysal
|
1mg/ mL (0.1%)
|
Ophthalmic Solution
|
Anti-allergy
|
Santen Pharmaceutical Co., Ltd.
|
Japan
|
Automatic Renewal
|
28 March 2022
|
30 May 2027
|
| View |
|
DR-XY25225
|
BUTAMIRATE CITRATE
|
SINECOD FORTE
|
7.5 mg/5mL
|
Syrup
|
Antitussive
|
Internphil Laboratories, Inc.
|
Philippines
|
Renewal
|
09 March 2024
|
18 May 2029
|
| View |
|
DR-XY25228
|
Loperamide Hydrochloride
|
Lorban
|
2 mg
|
Capsule
|
Antimotility
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
22 January 2024
|
25 May 2029
|
| View |
|
DR-XY25262
|
Eicosapentaenoic acid (EPA) ethyl ester + Docosahexaenoic acid (DHA) ethyl ester
|
Omacor
|
460 mg/380 mg
|
Softgel Capsule
|
Antihyperlipidemia
|
BASF AS
|
Norway
|
Renewal
|
21 March 2019
|
28 May 2029
|
| View |
|
DR-XY25291
|
Fluorometholone
|
Flulon
|
0.1% w/ v
|
Ophthalmic suspension
|
Corticosteroid / Anti-infective
|
Santen Pharmaceutical Co., Ltd.
|
Japan
|
Automatic Renewal
|
28 September 2022
|
29 November 2027
|
| View |
|
DR-XY25303
|
Rabeprazole Sodium
|
Pariet
|
20mg
|
Tablet
|
Proton Pump Inhibitor
|
Bushu Pharmaceuticals Ltd.
|
Japan
|
Renewal
|
25 July 2024
|
08 June 2030
|
| View |
|
DR-XY25304
|
Rabeprazole Sodium
|
Pariet
|
10mg
|
Tablet
|
Proton Pump Inhibitor
|
Bushu Pharmaceuticals Ltd.
|
Japan
|
Renewal
|
30 June 2024
|
08 June 2030
|
| View |
|
DR-XY25316
|
Calcium (as gluconate)
|
None
|
100 mg/mL (10% w/v) (equivalent to 137.50 mg Calcium-glucono-galacto-gluconate)
|
Solution For Injection (IV)
|
Electrolyte Solution
|
Harson Laboratories
|
India
|
Renewal
|
22 November 2023
|
14 June 2029
|
| View |
|
DR-XY25319
|
Ascorbic Acid
|
Mycee
|
100mg/Ml
|
Syrup (Oral Drops)
|
Vitamin
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
24 June 2024
|
14 June 2029
|
| View |
|
DR-XY25359
|
Finasteride
|
Propecia
|
1mg
|
Tablet
|
Testosterone-5-Alpha Reductase Inhibitors
|
AIAIC International Pharma, LLC
|
U.S.A.
|
Automatic Renewal
|
14 May 2023
|
21 May 2028
|
| View |
|
DR-XY25365
|
Hydroxyurea
|
Krabinex
|
500 mg
|
Capsule
|
Antineoplastic
|
Korea United Pharm. Inc.
|
Korea
|
Initial (Variation)
|
07 March 2024
|
07 March 2029
|
| View |
|
DR-XY25408
|
Tropicamide + Phenylephrine Hydrochloride
|
Sanmyd-P
|
5mg/ 5mg per mL
|
Ophthalmic solution
|
Mydriatic Agent
|
Santen Pharmaceutical Co., Ltd.
|
Japan
|
Automatic Renewal
|
30 December 2021
|
23 March 2027
|
| View |
|
DR-XY25409
|
Sodium Hyaluronate
|
Hialid
|
1mg/ mL (0.1%)
|
Ophthalmic solution
|
Eye Moisturizer/ Lubricant
|
Santen Pharmaceutical Co., Ltd.
|
Japan
|
Automatic Renewal
|
10 November 2022
|
18 December 2027
|
| View |
|
DR-XY25417
|
Ganciclovir
|
Virgan
|
1.5mg/g
|
Ophthalmic Gel
|
Antiviral
|
Farmila-Thea Farmaceutici S.P.A.
|
France
|
Renewal
|
02 August 2024
|
13 October 2029
|
| View |
|
DR-XY25423
|
Doxurubicin Hydrochloride
|
Ebedoxo
|
50 mg/25 mL (2 mg/mL)
|
Solution For Injection (I.V./I.A./Intravesicular)
|
Antineoplastic
|
Ebew Pharma Ges. M.b.H. Nfg. KG
|
Austria
|
Renewal
|
07 February 2024
|
28 July 2029
|
| View |
|
DR-XY25424
|
Doxorubicin Hydrochloride
|
Ebedoxo
|
10 mg/5 mL (2 mg/mL)
|
Solution For Injection (I.V./I.A./Intravesicular)
|
Antineoplastic
|
Ebew Pharma Ges. M.b.H. Nfg. KG
|
Autria
|
Renewal
|
23 February 2024
|
28 July 2029
|
| View |
|
DR-XY25463
|
Ambroxol Hydrochloride
|
Voxoll
|
30 mg
|
Tablet
|
Expectorant (Mucolytic)
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
17 May 2024
|
17 August 2029
|
| View |
DR-XY25482_PI_01.pdf
|
DR-XY25482
|
Lercanidipine
|
Zanidip
|
10mg
|
Tablet
|
Calcium Channel Blocker (Dihydropyridine derivatives)
|
Recordati Industria Chimica e Farmaceutica S.p.A.
|
Italy
|
Renewal
|
27 October 2024
|
15 December 2029
|
| View |
|
DR-XY25496
|
Dactinomycin
|
Trepar
|
500 mcg
|
Lyophilized Powder For Injection (I.V.)
|
Antineoplastic (Cell Cycle Non-Specific Agent)
|
Korea United Pharm. Inc.
|
Korea
|
Renewal
|
29 March 2024
|
10 September 2029
|